Related references
Note: Only part of the references are listed.Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Matias Autio et al.
HAEMATOLOGICA (2021)
Higher infiltration of intratumoral CD25+FOXP3+lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma
Chen Chang et al.
LEUKEMIA & LYMPHOMA (2021)
High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup
Marie F. Breinholt et al.
HEMATOLOGICAL ONCOLOGY (2021)
Gene expression profiling-based risk prediction and profiles of immune infiltration in diffuse large B-cell lymphoma
Selin Merdan et al.
BLOOD CANCER JOURNAL (2021)
MYC Enhances Cholesterol Biosynthesis and Supports Cell Proliferation Through SQLE
Fan Yang et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma
Zhongqi Li et al.
FRONTIERS IN ONCOLOGY (2021)
Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenstrom macroglobulinemia
Cecile Tomowiak et al.
BLOOD ADVANCES (2021)
Identifying Immune Cell Infiltration and Effective Diagnostic Biomarkers in Rheumatoid Arthritis by Bioinformatics Analysis
Sheng Zhou et al.
FRONTIERS IN IMMUNOLOGY (2021)
Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma
Xiang-Nan Jiang et al.
FRONTIERS IN ONCOLOGY (2021)
Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis
Yan Qin et al.
JOURNAL OF CANCER (2021)
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Xiaobo Wang et al.
CELL METABOLISM (2020)
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Bruno Bockorny et al.
NATURE MEDICINE (2020)
A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation
Beiying An et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances
Yichen Xu et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
Ying Jiang et al.
NATURE (2019)
Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3
Ting Yuan et al.
ONCOLOGY LETTERS (2019)
Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis
Fan Yang et al.
CANCER RESEARCH (2019)
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
Isha Kapoor et al.
CELL DEATH & DISEASE (2019)
Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma
Zi-Zhen Xu et al.
LEUKEMIA & LYMPHOMA (2018)
A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
Agnes Figueras et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies
Amnon Peled et al.
CYTOKINE (2018)
Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
Dabin Liu et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)
Ori Wald
JOURNAL OF CLINICAL MEDICINE (2018)
FOXO Signaling Pathways as Therapeutic Targets in Cancer
Mohd Farhan et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2017)
CXCL12-CXCR4 Axis Is Required for Contact-Mediated Human B Lymphoid and Plasmacytoid Dendritic Cell Differentiation but Not T Lymphoid Generation
Hirohito Minami et al.
JOURNAL OF IMMUNOLOGY (2017)
Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin
Jonathan S. Rink et al.
MOLECULAR PHARMACEUTICS (2017)
mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells
Walaa Eid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
CHOLESTEROL SENSING Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex
Brian M. Castellano et al.
SCIENCE (2017)
Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway
Yingjun Wang et al.
ONCOTARGET (2017)
Cholesterol Enhances Colorectal Cancer Progression via ROS Elevation and MAPK Signaling Pathway Activation
Caihua Wang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Structural Insights into the Niemann-Pick C1 (NPC1)-Mediated Cholesterol Transfer and Ebola Infection
Xin Gong et al.
CELL (2016)
CXCR4 signaling in health and disease
Tommaso Pozzobon et al.
IMMUNOLOGY LETTERS (2016)
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Fritz Offner et al.
BLOOD (2015)
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma
Jiayu Chen et al.
ONCOTARGET (2015)
Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)
John P. Leonard et al.
BLOOD (2015)
Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance
Agata Majchrzak et al.
MOLECULES (2014)
Cholesterol selectively activates canonical Wnt signalling over non-canonical Wnt signalling
Ren Sheng et al.
NATURE COMMUNICATIONS (2014)
Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy
Ho Cheol Shin et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2014)
Emerging targets in cancer management: role of the CXCL12/CXCR4 axis
Anna Dubrovska et al.
OncoTargets and Therapy (2013)
Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists
Yanping Hu et al.
LEUKEMIA & LYMPHOMA (2012)
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Gonzalo Gutierrez-Garcia et al.
BLOOD (2011)
mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway
Timothy R. Peterson et al.
CELL (2011)
The role of CXC chemokines and their receptors in cancer
Jo Vandercappellen et al.
CANCER LETTERS (2008)
Cyclophilin a is required for CXCR4-mediated nuclear export of heterogeneous nuclear ribonucleoprotein a2, activation and nuclear translocation of ERK1/2, and chemotactic cell migration
Heng Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Regulation of CXCR4 signaling
John M. Busillo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2007)
TNF-α mediates SDF-1α-induced NF-κB activation and cytotoxic effects in primary astrocytes
YL Han et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
